This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
Product Innovation Drives Illumina, Downbeat Margins a Woe
by Zacks Equity Research
Illumina (ILMN) harbors hopes about recent launches like NovaSeq S4 flow cell and reagent kit for its NovaSeq 6000 System. A low margin scenario due to the NovaSeq launch is a concern.
INSYS Therapeutics (INSY) Soars: Stock Adds 15.2% in Session
by Zacks Equity Research
INSYS Therapeutics (INSY) was a big mover last session, as the company saw its shares rise more than 15% on the day amid huge volumes.
PRA Health (PRAH) Hits 52-Week High on Multiple Positives
by Zacks Equity Research
PRA Health (PRAH) touches 52-week high on consistent revenue performance and Symphony Health integration.
Zimmer Biomet Suffers a Dull Knee Business & Supply Delay
by Zacks Equity Research
Zimmer Biomet (ZBH) fights challenges like supply delay of certain products that curb its capacity to regain lost US-based customers and net in the new ones.
Zimmer Biomet (ZBH) Surges: Stock Moves 6.1% Higher
by Zacks Equity Research
Zimmer Biomet (ZBH) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.
GW Pharmaceuticals (GWPH) Soars: Stock Adds 5.5% in Session
by Zacks Equity Research
GW Pharmaceuticals (GWPH) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
Bio-Rad (BIO) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Bio-Rad (BIO) consistently invests in R&D for product innovation.
Illumina Teams Up With Telegraph Hill to Form Verogen
by Zacks Equity Research
Illumina (ILMC) and Telegraph Hill Partners plan to set up Verogen to accelerate adoption of NGS in the global forensic genomics market.
Bio-Rad (BIO) Misses Q2 Earnings & Sales, Margin Declines
by Zacks Equity Research
Bio-Rad's (BIO) sales declined on ERP-related disruption. Margin pressure continues.
Should You Buy Bio-Rad Laboratories (BIO) Ahead of Earnings?
by Zacks Equity Research
Bio-Rad Laboratories (BIO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Can PerkinElmer (PKI) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
Despite an upbeat outlook, volatility in the foreign exchange rate is likely to mar PerkinElmer's (PKI) results in the second quarter.
Cardiovascular Systems (CSII) in Focus: Stock Moves 8.4% Higher
by Zacks Equity Research
Cardiovascular Systems, Inc. (CSII) was a big mover last session, as the company saw its shares rise over 8% on the day.
Bio-Rad (BIO) Scores a Strong Buy Right Now: Here's How
by Zacks Equity Research
Bio-Rad Laboratories, Inc. (BIO) has rallied 12.9% over the last three months, ahead of the S&P 500's 4.3% gain.
Health Care Battle Rages On: 2 MedTech Stocks to Buy
by Zacks Equity Research
Let's focus on two MedTech Stocks which are fundamentally strong amidst the volatile market condition.
Capital Senior Living (CSU) in Focus: Stock Moves 5.8% Higher
by Zacks Equity Research
Capital Senior Living Corporation (CSU) was a big mover last session, as the company saw its shares rise almost 6% on the day.
Omeros (OMER) Worth a Look: Stock Adds 11.8% in Session
by Zacks Equity Research
Omeros Corporation (OMER) shares rose almost 12% in the last trading session.
What Falling Estimates & Price Mean for Eagle Pharmaceuticals (EGRX)
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Imprimis Pharmaceuticals (IMMY) Looks Good: Stock Up 13%
by Zacks Equity Research
Imprimis Pharmaceuticals, Inc. (IMMY) shares rose over 13% in the last trading session.
Five Stocks Rocketing Higher on Huge Momentum
by David Bartosiak
The bears were sent running, screaming towards their caves today as the market started strong and didn???t look back at all
TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1
by Zacks Equity Research
TransEnterix, Inc. (TRXC) reported a loss of 13 cents per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 12 cents.
Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up
by Zacks Equity Research
Masimo Corp. (MASI) reported earnings of 57 cents per share in the first quarter of 2017, outperforming the Zacks Consensus Estimate of 54 cents and improving from the year-ago quarterly earnings of 53 cents.
Medtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite
by Zacks Equity Research
Medtronic plc (MDT) recently won FDA approval for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers that improve therapy delivery for patients with heart failure.
STERIS (STE) Grapples with Headwinds: Should You Dump?
by Zacks Equity Research
On May 10, we issued an updated research report on STERIS Plc (STE) which manufactures and markets infection prevention, decontamination, microbial reduction, and surgical and gastrointestinal support products and services.
Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View
by Zacks Equity Research
Hologic Inc. (HOLX) reported second-quarter fiscal 2017 adjusted earnings per share (EPS) of 50 cents, up 6.4% year over year.
Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates
by Zacks Equity Research
Genomic Health, Inc. (GHDX) reported first-quarter 2017 loss per share of 7 cents, reflecting an improvement from the year-ago quarter's loss figure of 19 cents.